Literature DB >> 15569811

Preventing venous thromboembolism in acute medical patients.

A Elis1, M H Ellis.   

Abstract

BACKGROUND: While extensive data support the clinical benefit and cost-effectiveness of routine thromboprophylaxis in surgical patients, the use of this approach in medical patients has been controversial. However, recent data, mainly from the MEDENOX trial, support routine thromboprophylaxis in acutely ill medical patients. AIM: To determine attitudes towards VTE prevention in such patients, in departments of internal medicine in Israel.
DESIGN: Questionnaire-based survey.
METHODS: A questionnaire regarding aspects of VTE prophylaxis was mailed to all heads of internal medicine departments in Israel (n = 90). The questionnaire also included data concerning VTE prevention measures in specific acute medical illnesses, based on the MEDENOX study population.
RESULTS: Fifty-eight (64%) departments returned the questionnaire. Forty-seven (81%) of them considered VTE a clinical problem in their departments, but only 37 (63%) had a routine VTE prevention policy. The most frequently used modality for VTE prophylaxis was low-molecular-weight heparin. There was little agreement concerning the exact indications or risk factors in which VTE prophylaxis measures should be used, except the combination of acute medical disabling illness and previous VTE. DISCUSSION: The results emphasize the need for detailed guidelines and risk assessment models for VTE prevention treatments in acutely ill medical patients, as well as better education for physicians.

Entities:  

Mesh:

Year:  2004        PMID: 15569811     DOI: 10.1093/qjmed/hch128

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  3 in total

1.  Venous thromboembolism in COPD hospitalized patients.

Authors:  Raquel Barba; Antonio Zapatero; Javier Marco; Juan E Losa; Susana Plaza; Jose Manuel Casas; Jesús Canora
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

2.  The AVAIL ME study: a multinational survey of VTE risk and prophylaxis.

Authors:  Ali T Taher; Joseph Aoun; Pascale Salameh
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

3.  Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients : a prospective, uncontrolled cohort study.

Authors:  Francisco Miras-Parra; Emilia Navascués-Martínez; Antonio Gómez-Outes; Javier Martínez-González; Eduardo Rocha
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.